Pharmacotherapy in Diabetic Neuropathy

  • Anders Dejgaard
  • Jannik Hilsted

Diabetic neuropathy was defined at the San Antonio Consensus Conference as “a descriptive term meaning a demonstrable nerve disorder, either clinically evident or subclinical, that occurs in the setting of diabetes mellitus without other causes for peripheral neuropathy. The neuropathic disorder includes manifestations in the somatic or autonomic parts of the peripheral nervous system” [1]. Diabetic neuropathy is a chronic condition caused by hyperglycaemia, characterized by progressive morphological destruction of the peripheral nervous system, accompanied by loss of peripheral nerve function. Clinically, loss of function is defined by distal loss of sensibility, muscular strength and loss of deep tendon reflexes as well as by autonomic dysfunction of viscera and blood vessels.


Diabetic Neuropathy Autonomic Neuropathy Nerve Conduction Velocity Diabetic Peripheral Neuropathy Painful Diabetic Neuropathy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Consensus statement. Report and recommendation of the San Antonio Conference on diabetic neuropathy. American Diabetes Association American Academy of Neurology. Diabetes Care 1988;11:592–597.Google Scholar
  2. 2.
    Pirart J. Diabetes mellitus and its generative complications: A prospective study of 4400 patients observed. Diabetes Care 1978;1:168–188.Google Scholar
  3. 3.
    DCCT research group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977–986.CrossRefGoogle Scholar
  4. 4.
    UK Prospective Diabetes Study group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes. Lancet 1998;352:837–853.CrossRefGoogle Scholar
  5. 5.
    Duby JJ, Campbell RK, Setter SM et al. Diabetic neuropathy: An intensive review. Am J Health Syst Pharm 2004;61:160–173.PubMedGoogle Scholar
  6. 6.
    Sima AAF, Pierson CR. Pathogenesis and Pathology of diabetic neuropathy. In: Gries FA, editor. Textbook of diabetic neuropathy, Stuttgart. New York: Georg Thieme verlag, 2003, 83–169.Google Scholar
  7. 7.
    Boel E, Selmer J, Flodgaard HJ et al. Diabetic late complications: Will aldose reductase inhibitors or inhibitors of advanced glycosylation endproducts formation hold promise? J Diab Compl 1995;9:104–129.CrossRefGoogle Scholar
  8. 8.
    Dyck P. Pathology and pathophysiology- Human and experimental. In Dyck PJ, editor. Diabetic neuropathy. London: WB Saunders Company, 1987, 223–237.Google Scholar
  9. 9.
    Dejgaard A, Gade A, Larsson H et al. Evidence of diabetic encephalopathy. Diabet Med 1991;8:162–167.CrossRefPubMedGoogle Scholar
  10. 10.
    Garrow AP, Boulton AJM. Vibration perception threshold- a valuable assessment of neural dysfunction in people with diabetes. Diabet Metab Res Rev 2006;22:411–441.CrossRefGoogle Scholar
  11. 11.
    Dejgaard A. Pathophysiology and treatment of diabetic neuropathy. Diabet Med 1988;15:97–112.CrossRefGoogle Scholar
  12. 12.
    Jensen TS, Backonja M, Jimenez SH et al. New perspectives on the management of diabetic peripheral neuropathic pain. Diabet Vasc Dis Res 2006;3(2):108–119.CrossRefGoogle Scholar
  13. 13.
    Martin CL, Albers J, Herman WH et al. Neuropathy among the diabetes control and complications trial cohort 8 years after trial completion. Diabetes Care 2006;29:340–304.CrossRefPubMedGoogle Scholar
  14. 14.
    Allen RDM, Al-Habri IS, Morris JGL et al. Diabetic neuropathy after pancreas transplantation: determinants on recovery. Transplantation 1997;63:830–838.CrossRefPubMedGoogle Scholar
  15. 15.
    Sima AAF. Pathological mechanisms involved in diabetic neuropathy: Can we slow the process? Curr Opin Investig Drugs 2006;7(4):324–337.PubMedGoogle Scholar
  16. 16.
    Ekberg K, Brismar T, Johansson BL et al. Amelioration of sensory nerve dysfunction by C-peptide in patients with Type 1 Diabetes. 2003;52:536–541.Google Scholar
  17. 17.
    Obrosova IG, Pacher P, Szab C et al. Aldose reductase inhibition counteracts oxidative-nitrosative stress and poly(ADP-ribose) polymerase activation in tissue sites for diabetic complications. Diabetes Nutr Metab. 2005;54:234–242.Google Scholar
  18. 18.
    Hotta N, Akanuma Y, Kawamori R et al. Long-term clinical effects of Epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy. Diabetes Care 2006;29(7):1538–1544.CrossRefPubMedGoogle Scholar
  19. 19.
    Bril V, Buchanan RA, Ranistat study group. Long term effects of ranirestat on peripheral nerve function in patients with diabetic sensimotor polyneuropathy. Diabetes Care 2006;29(1):68–72.CrossRefPubMedGoogle Scholar
  20. 20.
    Vincent MV, Feldman EL. New insights into the mechanism of diabetic neuropathy. Rev Endocr Metab Disord 2004;5(3):227–236.CrossRefPubMedGoogle Scholar
  21. 21.
    The SYDNEY trial. The sensory symptoms of diabetic polyneuropathy are improved with alfa-lipoic acid. Diabetes Care. 2003;26:770–776.CrossRefGoogle Scholar
  22. 22.
    Tankova T, Chernikova S, Koev D. Treatment for diabetic mononeuropathy with alfa-lipoic acid. Int J Clin Pract 2005;59(6):645–650.CrossRefPubMedGoogle Scholar
  23. 23.
    Peyroux J, Sternberg M. Advanced glycation endproducts (AGEs): pharmacological inhibition in diabetes. Pathologie Biologie 2006;54:405–419.CrossRefPubMedGoogle Scholar
  24. 24.
    Goldin A, Beckman JA, Schmidt AM et al. Advanced glycation end products- sparking the development of diabetic vascular injury. Circulation 2006;114:597–605.CrossRefPubMedGoogle Scholar
  25. 25.
    Cameron NE, Eaton SEM, Cotter MA et al. Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy. Diabetologia 2001; 44:1973–1988.CrossRefPubMedGoogle Scholar
  26. 26.
    Keen H, Payan J, Allawi J. et al. Treatment of diabetic neuropathy with gamma-linolenic acid. Diabetes Care 1993;16:8–15.CrossRefPubMedGoogle Scholar
  27. 27.
    Apfel SC, Schwartz S, Adornato BT et al. Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy: A randomized controlled trial. rhNGF Clinical Investigator Group. JAMA 2000;284(17):2215–21.CrossRefPubMedGoogle Scholar
  28. 28.
    Argoff C, Backonia MM, Belgrade MJ et al. Consensus guidelines: Treatment planning and options. Mayo Clin Proc. 2006;81:s12–s25.CrossRefPubMedGoogle Scholar
  29. 29.
    Boulton AJM. Management of diabetic peripheral neuropathy. Clin Diab. 2005;23(1):9–15.CrossRefGoogle Scholar
  30. 30.
    Vinik A. Clinical review: Use of antiepileptic drugs in the treatment of chronic painful diabetic neuropathy. J Clin Endocrinol Metab 2005;90:4936–4945.CrossRefPubMedGoogle Scholar
  31. 31.
    Morello CM, Leckband SG, Stoner CP et al. Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. ArchIntern Med 1999;159:1931–1937.Google Scholar
  32. 32.
    Griesing T, Freeman R Rosenstock et al. Efficacy, safety and tolerability og pregabalin treatment for diabetic peripheral neuropathy: findings from 6 randomized controlled trials. Diabetologia 2005;48 (suppl 1):A351.Google Scholar
  33. 33.
    Grosskopf J, Mazzola J, Wan J et al. A randomized, placebo controlled study of oxcarbazepine in painful diabetic neuropathy. Acta Neurol Scand 2006;114:177–180.CrossRefPubMedGoogle Scholar
  34. 34.
    Kastrup J, Petersen P, Dejgaard et al. Treatment of chronic diabetic neuropathy with intravenouis lidocaine infusion. Br Med J 1986;292:173–174.CrossRefGoogle Scholar
  35. 35.
    Dejgaard A, Petersen P, Kastrup J. Mexilitine for treatment of chronic diabetic neuropathy. Lancet 1988;29:9–11.CrossRefGoogle Scholar
  36. 36.
    Sindrup SH, Andersen G, Madsen C et al. Tramadol relieves pain and allodynia in polyneuropathy: a randomised double blind, controlled trial. Pain 1999;83:85–90.CrossRefPubMedGoogle Scholar
  37. 37.
    Jensen PG, Larson R. Management of painful diabetic neuropathy. Drugs and aging. 2001;18(10):737–749.CrossRefPubMedGoogle Scholar
  38. 38.
    Vinik AI. Diabetic neuropathies. Med Clin N Am 2004;88:947–999.CrossRefPubMedGoogle Scholar
  39. 39.
    Boulton AJM, Vinik AI, Arezo JC et al. Diabetic neuropathies. Diabetes Care 2005;28(4):956–962.CrossRefPubMedGoogle Scholar
  40. 40.
    Brownlee M. The pathobiology of diabetic complications – a unifying mechanism. Diabetes 2005;54: 1615–1625.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Anders Dejgaard
    • 1
  • Jannik Hilsted
    • 2
  1. 1.Novo Nordisk A/SDenmark
  2. 2.RigshospitaletUniversity of CopenhagenDenmark

Personalised recommendations